chimerix

Durham biotech Chimerix promotes exec to CFO

Posted by WRAL TechWire | Dec 5, 2023

Durham-based biopharmaceutical Chimerix, has promoted Michelle LaSpaluto, current vice president of corporate financial planning and investor relations, to chief financial officer.

Bad day on Street: CommScope, Chimerix, Biocryst all report losses

Posted by WRAL TechWire | Aug 3, 2023

Earnings news out early Thursday before the markets opened was not good news for CommScope, Chimerix and Biocryst. Here are the details.

Durham pharma Chimerix promotes its chief biz officer to CEO

Posted by WRAL TechWire | Jun 28, 2023

DURHAM – Mike Andriole, a longtime veteran executive at Eli Lilly, is the new CEO at Durham-based pharmaceutical firm Chimerix. Andriole had been chief business officer and chief financial officer at the company. He replaces Mike Sherman, who retired as CEO and is now chair of the company’s board....

Chimerix reports loss but CEO sees progress in drugs targeting brain tumors

Posted by WRAL TechWire | May 4, 2023

Chimerix on Thursday sees progress being made with the drug company’s pipeline even though it reported a loss of $21.4 million in its first quarter.

Durham drug firm Chimerix rejects call from stockholder for liquidation

Posted by WRAL TechWire | Nov 11, 2022

Shares in Durham-based pharmaceutical firm Chimerix are surging after the company rejected a call from a major stockholder to liquidate the company.

North Carolina Collaboratory awards 11 grants worth millions to universities, business partners such as SAS, Chimerix

Posted by WRAL TechWire | Nov 9, 2022

The North Carolina Collaboratory, headquartered at the University of North Carolina at Chapel Hill, is awarding 11 research and development grants through a new competitive Business-Academia Partnership Program to help address the public health and economic impacts of COVID-19 in North Carolina.

Durham biopharma company Chimerix completes $238M+ deal

Posted by Jason Parker | Sep 27, 2022

Chimerix has completed a $238 million deal announced earlier this year with the possibility of the amount rising to $325 million plus royalties.

Durham biopharma Chimerix wins contract worth as much as $680M for smallpox treatment

Posted by WRAL TechWire | Aug 30, 2022

Biopharma Chimerix has landed a contract worth as much as $680 million with the federal government for its smallpox treatment TEMBEXA, which was approved by the FDA.